- Advanced search
- Immuno Portal
- Malaria Portal
Compound class: Antibody
Comment: Gimsilumab (MORAb-022) is an investigational, fully human IgG1 monoclonal antibody being evaluated for its potential in the treatment of multiple inflammatory diseases and cancer. It targets granulocyte-macrophage colony stimulating factor (GM-CSF, CSF2), a growth factor involved in autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis and asthma. In the cancer setting, MORAb-022-mediated blocking of CSF2 produces a pro-immunity microenvironment that leads to tumour tissue death in preclinical studies. Peptide sequences (from the WHO INN submission for gimsilumab) match sequences 8 and 12 from Morphotek Inc. patent WO2007092939 , and these sequences belong to monoclonal antibody clone G9 specified in the patent.
|No information available.|
|Summary of Clinical Use|
|Phase 1 study (NCT01357759) in healthy volunteers and patients with rheumatoid arthritis has been completed.
SARS-CoV-2 and COVID-19: In response to the urgent medical need caused by SARS-CoV-2, gimsilumab is being investigated for anti-inflammatory potential in COVID-19 patients. The hypothesis being to reduce the raging cytokine storm that can arise secondary to SARS-CoV-2 infection.
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT01357759||Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects||Phase 1 Interventional||Morphotek|
|NCT04351243||A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19.||Phase 2 Interventional||Kinevant Sciences GmbH||A repurposing effort to try to meet the unmet clinical need of patients with severe COVID-19.|